Cargando…

Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma

BACKGROUND: Circulating thyrotropin receptor messenger ribonucleic acid (TSHR mRNA) assay has been validated in the follow-up of differentiated thyroid carcinoma (DTC) because of its high sensitivity during thyroid hormone therapy and no interference with endogenous anti-thyroglobulin antibodies (Tg...

Descripción completa

Detalles Bibliográficos
Autores principales: Ausavarat, Surasawadee, Sriprapaporn, Jiraporn, Satayaban, Busara, Thongnoppakhun, Wanna, Laipiriyakun, Aunchalee, Amornkitticharoen, Boontham, Chanachai, Rujaporn, Pattanachak, Chaveevan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523908/
https://www.ncbi.nlm.nih.gov/pubmed/26244057
http://dx.doi.org/10.1186/s13044-015-0024-4
_version_ 1782384132907597824
author Ausavarat, Surasawadee
Sriprapaporn, Jiraporn
Satayaban, Busara
Thongnoppakhun, Wanna
Laipiriyakun, Aunchalee
Amornkitticharoen, Boontham
Chanachai, Rujaporn
Pattanachak, Chaveevan
author_facet Ausavarat, Surasawadee
Sriprapaporn, Jiraporn
Satayaban, Busara
Thongnoppakhun, Wanna
Laipiriyakun, Aunchalee
Amornkitticharoen, Boontham
Chanachai, Rujaporn
Pattanachak, Chaveevan
author_sort Ausavarat, Surasawadee
collection PubMed
description BACKGROUND: Circulating thyrotropin receptor messenger ribonucleic acid (TSHR mRNA) assay has been validated in the follow-up of differentiated thyroid carcinoma (DTC) because of its high sensitivity during thyroid hormone therapy and no interference with endogenous anti-thyroglobulin antibodies (TgAb) compared to serum thyroglobulin (Tg). We investigated the efficacy of TSHR mRNA assay in 160 DTC patients using quantitative PCR (qPCR). FINDINGS: Only TSHR mRNA level of structural persistent disease with TgAb-positive (3.47 (2.97–9.53) pg equivalents/μg total RNA; p = 0.013) and its subgroup of distant metastasis patients with TgAb-positive (5.55 (3.28–12.52) pg equivalents/μg total RNA; p = 0.009) were significantly different from patients with no evidence of disease (2.32 (1.44–3.94) pg equivalents/μg total RNA). Applying cutoff at 2.00 pg equivalents/μg total RNA enabled us to predict structural persistent disease patients with a sensitivity of 62.3 % and a specificity of 42.9 %. Although, the sensitivity of TSHR mRNA assay in TgAb-postive patients (88.2 %) was superior than serum Tg (47.1 %) (p = 0.00002), the accuracy of the test is only 54.5 %. CONCLUSIONS: This study demonstrated that TSHR mRNA assay has good sensitivity in TgAb-positive patients but it is neither specific enough as a first-line of testing nor a surrogate marker in the follow-up of our DTC patients.
format Online
Article
Text
id pubmed-4523908
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45239082015-08-05 Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma Ausavarat, Surasawadee Sriprapaporn, Jiraporn Satayaban, Busara Thongnoppakhun, Wanna Laipiriyakun, Aunchalee Amornkitticharoen, Boontham Chanachai, Rujaporn Pattanachak, Chaveevan Thyroid Res Short Report BACKGROUND: Circulating thyrotropin receptor messenger ribonucleic acid (TSHR mRNA) assay has been validated in the follow-up of differentiated thyroid carcinoma (DTC) because of its high sensitivity during thyroid hormone therapy and no interference with endogenous anti-thyroglobulin antibodies (TgAb) compared to serum thyroglobulin (Tg). We investigated the efficacy of TSHR mRNA assay in 160 DTC patients using quantitative PCR (qPCR). FINDINGS: Only TSHR mRNA level of structural persistent disease with TgAb-positive (3.47 (2.97–9.53) pg equivalents/μg total RNA; p = 0.013) and its subgroup of distant metastasis patients with TgAb-positive (5.55 (3.28–12.52) pg equivalents/μg total RNA; p = 0.009) were significantly different from patients with no evidence of disease (2.32 (1.44–3.94) pg equivalents/μg total RNA). Applying cutoff at 2.00 pg equivalents/μg total RNA enabled us to predict structural persistent disease patients with a sensitivity of 62.3 % and a specificity of 42.9 %. Although, the sensitivity of TSHR mRNA assay in TgAb-postive patients (88.2 %) was superior than serum Tg (47.1 %) (p = 0.00002), the accuracy of the test is only 54.5 %. CONCLUSIONS: This study demonstrated that TSHR mRNA assay has good sensitivity in TgAb-positive patients but it is neither specific enough as a first-line of testing nor a surrogate marker in the follow-up of our DTC patients. BioMed Central 2015-08-04 /pmc/articles/PMC4523908/ /pubmed/26244057 http://dx.doi.org/10.1186/s13044-015-0024-4 Text en © Ausavarat et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Report
Ausavarat, Surasawadee
Sriprapaporn, Jiraporn
Satayaban, Busara
Thongnoppakhun, Wanna
Laipiriyakun, Aunchalee
Amornkitticharoen, Boontham
Chanachai, Rujaporn
Pattanachak, Chaveevan
Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma
title Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma
title_full Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma
title_fullStr Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma
title_full_unstemmed Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma
title_short Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma
title_sort circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523908/
https://www.ncbi.nlm.nih.gov/pubmed/26244057
http://dx.doi.org/10.1186/s13044-015-0024-4
work_keys_str_mv AT ausavaratsurasawadee circulatingthyrotropinreceptormessengerribonucleicacidisnotaneffectivemarkerinthefollowupofdifferentiatedthyroidcarcinoma
AT sriprapapornjiraporn circulatingthyrotropinreceptormessengerribonucleicacidisnotaneffectivemarkerinthefollowupofdifferentiatedthyroidcarcinoma
AT satayabanbusara circulatingthyrotropinreceptormessengerribonucleicacidisnotaneffectivemarkerinthefollowupofdifferentiatedthyroidcarcinoma
AT thongnoppakhunwanna circulatingthyrotropinreceptormessengerribonucleicacidisnotaneffectivemarkerinthefollowupofdifferentiatedthyroidcarcinoma
AT laipiriyakunaunchalee circulatingthyrotropinreceptormessengerribonucleicacidisnotaneffectivemarkerinthefollowupofdifferentiatedthyroidcarcinoma
AT amornkitticharoenboontham circulatingthyrotropinreceptormessengerribonucleicacidisnotaneffectivemarkerinthefollowupofdifferentiatedthyroidcarcinoma
AT chanachairujaporn circulatingthyrotropinreceptormessengerribonucleicacidisnotaneffectivemarkerinthefollowupofdifferentiatedthyroidcarcinoma
AT pattanachakchaveevan circulatingthyrotropinreceptormessengerribonucleicacidisnotaneffectivemarkerinthefollowupofdifferentiatedthyroidcarcinoma